Financial Data and Key Metrics Changes - SCYNEXIS reported net product revenues of $1.3 million for BREXAFEMME in Q2 2022, nearly doubling from $700,000 in Q1 2022 [47] - R&D expenses increased to $7.1 million in Q2 2022 from $4.7 million in Q2 2021, while SG&A expenses rose to $15.8 million from $12.8 million in the same period [47] - Cash and cash equivalents totaled $118.7 million as of June 30, 2022, compared to $112.4 million a year earlier [48] Business Line Data and Key Metrics Changes - BREXAFEMME prescriptions grew by 29% quarter-over-quarter, with over 5,100 prescriptions in Q2 2022 [21][14] - The number of healthcare providers (HCPs) prescribing BREXAFEMME increased by 25% quarter-over-quarter, reaching over 2,200 HCPs [20] Market Data and Key Metrics Changes - Coverage for BREXAFEMME reached over 109 million commercially insured lives, representing approximately 60% of the commercial universe [23] - The company aims to increase coverage to 65% by the end of 2023 [59] Company Strategy and Development Direction - SCYNEXIS is focused on expanding the labeling and use of BREXAFEMME, with a PDUFA date set for November 30, 2022, for recurrent VVC indication [11] - The company plans to build a broad antifungal franchise and has several upcoming catalysts in 2022 and beyond [10][52] - The strategy includes enhancing HCP and patient campaigns to drive adoption and awareness of BREXAFEMME [18][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing adoption of BREXAFEMME despite macroeconomic headwinds [9] - The company anticipates that the approval of the recurrent VVC indication will significantly enhance prescriber confidence and drive prescription growth [11][19] - Management highlighted the potential for BREXAFEMME to generate $700 million to $800 million in annual net sales in the U.S. [52] Other Important Information - The company successfully raised $45 million in April 2022, providing a solid cash runway into Q1 2024 [15] - SCYNEXIS is conducting multiple studies, including the Phase 3b VANQUISH study and the MARIO study, to evaluate ibrexafungerp in various indications [12][43] Q&A Session Summary Question: What is the added market opportunity post-approval for recurrent VVC? - Management indicated that the new indication will provide significant opportunities for field teams to engage with physicians using fresh data [56] Question: What feedback has been received from physicians regarding BREXAFEMME? - Positive feedback was reported, highlighting the ease of use, one-day dosing, and quick symptom relief [58] Question: What is the target coverage by the end of the year? - The current coverage is 109 million lives, with a target of 65% of the commercial universe by the end of 2023 [59] Question: What are the copay ranges for patients? - Copays range from $5 to $600, with the majority falling between $30 to $50, which is considered acceptable [73] Question: What is the expected timeline for data from the FURI and CARES studies? - Data from these studies is expected in 2024, with the aim to wrap up activities in the first half of next year [66] Question: How is the company addressing the competition from Mycovia's product? - Management noted that Mycovia's product has a restricted label, which could benefit BREXAFEMME by highlighting its advantages [84]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended MARCH 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 001-36365 SCYNEXIS, Inc. (Exact name of registrant as specified in its charter) Delaware 56-2181648 (State or other jurisdiction of incor ...

SCYNEXIS, Inc. (NASDAQ:SCYX) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Marco Taglietti – President and Chief Executive Officer Christine Coyne – Chief Commercial Officer Dr. David Angulo – Chief Medical Officer Lawrence Hoffman – Interim Chief Financial Officer Debbie Etchison – Executive Director, Communications Conference Call Participants Michael Higgins – Ladenburg Thalmann Wayne Buchan – Cantor Fitzgerald Oren Livnat – H.C. Wainwright Operator Greetings and welcome t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36365 SCYNEXIS, Inc. (Exact name of registrant as specified in its charter) Delaware 56-2181648 (State or other jurisdiction of incor ...

SCYNEXIS, Inc. (NASDAQ:SCYX) Q4 2021 Earnings Conference Call March 29, 2022 8:30 AM ET Company Participants Debbie Etchison - Executive Director, Communications Marco Taglietti - President and Chief Executive Officer Christine Coyne - Chief Commercial Officer David Angulo - Chief Medical Officer Lawrence Hoffman - Interim Chief Financial Officer Conference Call Participants Carvey Leung - Cantor Fitzgerald Michael Higgins - Ladenburg Thalmann Oren Livnat - H.C. Wainwright Steve Brozak - WBB Securities Kuma ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 1 Evertrust Plaza, 13th Floor (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Com ...

SCYNEXIS, Inc. (NASDAQ:SCYX) Q3 2021 Earnings Conference Call November 10, 2021 8:30 AM ET Company Participants Debbie Etchison - Executive Director of Communications Marco Taglietti - President and Chief Executive Officer Christine Coyne - Chief Commercial Officer David Angulo - Chief Medical Officer Eric Francois - Chief Financial Officer Conference Call Participants Michael Higgins - Ladenburg Thalmann Kumaraguru Raja - Brookline Capital Markets Nathan Weinstein - Aegis Capital Michael Higgins - Ladenbur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Mark One) WASHINGTON, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-Q FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36365 SCYNEXIS, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or orga ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36365 SCYNEXIS, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or org ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36365 SCYNEXIS, Inc. (Exact name of registrant as specified in its charter) Delaware 56-2181648 (State or other jurisdiction of incor ...